Here are the DEF 14A proxy statements from Catheter Precision, Inc. (VTAK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.
Catheter Precision, Inc. (VTAK) is asking stockholders at the September 30, 2026 virtual annual meeting to approve several governance and capital-structure changes, alongside routine items. One proposal would reincorporate the company from Delaware to Nevada via a plan of conversion, eliminating Delaware franchise taxes of approximately $200,000 per year and adopting Nevada articles and bylaws that include annual election of all directors and broader director/officer liability protections, while opting out of certain Nevada anti-takeover statutes.
Stockholders are asked to elect David A. Jenkins as the sole Class II director, authorize a discretionary reduction in the conversion price of 9,489.488 Series J preferred shares (held entirely by Mr. Jenkins and his affiliate) from $1.56 down to as low as $0.23 per share, and approve issuance of up to 340,000 common shares upon exercise of Series M warrants granted to Mr. Jenkins and FatBoy Capital, L.P. The Series J amendment could increase the Series J conversion from 6,083,005 to approximately 41,258,209 shares, or about 217% of the 18,972,049 shares outstanding as of the record date.
Additional proposals would increase the 2023 Equity Incentive Plan share reserve by 5,000,000 shares (to 5,067,888 available shares before evergreen adjustments), and authorize a one-time repricing of 507,764 outstanding stock options to fair market value on the approval date, affecting executives, directors and employees. Stockholders are also asked to ratify WithumSmith+Brown, PC as auditor for 2027 and to approve potential adjournment/postponement to solicit additional proxies.
Catheter Precision, Inc. is asking stockholders at an April 15, 2026 virtual special meeting to approve several financing-related proposals and a potential reverse stock split. Stockholders of record as of March 9, 2026, when 2,357,127 common shares were outstanding, may vote.
The company seeks approval under NYSE American rules for common shares issuable from new Series C, Series D and Series J preferred stock structures and a reduced conversion price on existing Series B preferred stock. These preferred series could, at specified floor prices and assuming full participation, convert into large numbers of common shares, including up to 252,047,623 shares from Series C, 31,508,572 from Series D and 6,083,005 from Series J, plus an increase in Series B conversion capacity from 335,214 to 1,252,344 shares.
Stockholders are also being asked to authorize a reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑100, at the board’s discretion within one year, primarily to help the company maintain NYSE American listing standards and potentially broaden institutional interest.